Short answer
Coherus Oncology, Inc. (CHRS) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $12M (down 83.7% year over year) with net income of −$36M.
Q3 2025 key financials · XBRL
- Revenue
- $12M
- −83.7% YoY · +12.8% QoQ
- Net income
- −$36M
- −230.5% YoY · −111.9% QoQ
- Operating margin
- -383.1%
- EPS (diluted)
- −$0.31
- −287.5% YoY · −112.1% QoQ
Source: XBRL data from the Coherus Oncology, Inc. (CHRS) Q3 2025 10-Q on SEC EDGAR. USD.
Coherus Oncology, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $11.6M, up $5.5M YoY, driven by LOQTORZI revenue of $11.2M versus $5.8M
- Gross margin 68% versus 55% YoY, with LOQTORZI best-performing product line
- R&D expense $27.3M versus $22.1M YoY, led by CHS-114 and casdozokitug development
- Cash, equivalents and marketable securities $191.7M versus $126.0M at December 31, 2024
- 2025 outlook: higher revenue and R&D, lower SG&A and interest expense; continued LOQTORZI growth expected
Risk Factors
- Newly highlighted OBBBA risk: healthcare reform may raise commercialization costs and constrain LOQTORZI pricing
- Profitability risk intensified after UDENYCA Sale: LOQTORZI may not replace materially higher UDENYCA revenue
- Regulatory risk: FDA funding shortages, staffing limits, shutdowns, or health emergencies could delay inspections and approvals
- Competitive risk: LOQTORZI, CHS-114, and casdozokitug face significant immuno-oncology biologic competition
- Liquidity risk: $191.7 million in cash, equivalents, and marketable securities as of September 30, 2025; additional funding may be needed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Coherus Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.